DoD Pancreatic Cancer, Translational Research Partnership Award | W81XWH 21 PCARP TRPA

Opportunity Information: Apply for W81XWH 21 PCARP TRPA

The DoD Pancreatic Cancer, Translational Research Partnership Award (FY21 PCARP TRPA) is a Department of Defense funding opportunity designed to speed up the translation of promising pancreatic cancer ideas into real-world clinical use. Its core purpose is to build strong, genuinely collaborative teams that connect laboratory discovery with patient-focused clinical insight, so that advances in prevention, detection, diagnosis, prognosis, treatment, and survivorship can move more quickly toward application. The program emphasizes that translational progress is not just a one-direction path from bench to bedside; instead, it expects a two-way, ongoing exchange where clinical observations shape laboratory questions and laboratory findings meaningfully influence clinical strategy.

A central requirement of this award is a true partnership between two independent investigators: one must serve as a research scientist and the other must serve as a clinician investigator. The application has to make it obvious that both partners contributed equally and intellectually to the project design, rather than one person simply “supporting” the other. Multi-institutional and multidisciplinary teams are strongly encouraged, and the program explicitly welcomes collaborators who are not traditionally in the pancreatic cancer field, as long as their expertise strengthens the science and accelerates translation. At the same time, at least one of the two partners must bring direct experience in pancreatic cancer research or pancreatic cancer patient care to ensure the work stays anchored to the disease and its clinical realities.

The award mechanism is aimed at projects that are difficult to accomplish through separate, parallel efforts, meaning the success of the proposed research should depend on the unique skills and contributions of each partner. A key point is that the clinician partner cannot be included only to provide patient access, tissue samples, or a pathway to recruitment; that kind of limited role does not match the intent of the program. Instead, the clinician should be substantively involved in shaping the hypotheses, interpreting findings, and steering decisions based on real patient needs and clinical constraints, while the research scientist provides complementary expertise in mechanistic biology, model systems, technology development, analytics, or other discovery-driven approaches.

From a research scope standpoint, the program supports translational studies that may include correlative analyses, retrospective tissue work, and small pilot clinical trials, but it does not expect to fully support large-scale clinical trials. Applications are encouraged to incorporate clinical information in a way that closes knowledge gaps, clarifies outcomes, validates key findings, or extends potentially transformative early results toward practical use. The opportunity also recognizes that translational work may involve creating, improving, or using annotated biorepositories, and it values projects that thoughtfully connect biospecimens, clinical metadata, and outcomes to answer questions that matter for patients.

The opportunity highlights several major evaluation priorities. Partnership is a defining feature: reviewers will look for evidence that each investigator is essential and that the combined team can accomplish something neither could do alone. Translation is equally central: the proposal should demonstrate a reciprocal flow of information between basic and clinical science as the research plan is developed and executed, rather than treating the clinic as a simple source of materials or the lab as a one-time testing service. Impact is another key criterion, meaning the work should have a credible potential to significantly advance pancreatic cancer research and/or patient care and to accelerate movement into clinical applications. Feasibility must also be clear, including access to required specimens, datasets, patient populations, and/or interventions, depending on the project design.

Preliminary data is required and can be published or unpublished, as long as it is relevant to pancreatic cancer and the proposed work. The program also allows that the feasibility-supporting data do not need to originate directly from pancreatic cancer studies; preliminary observations can come from laboratory discoveries, population-based research, or real clinical experience, including patterns noticed in patient care. What matters is that the data support the rationale and practicality of the approach, and that the team can credibly execute the plan.

Because coordination is central to this mechanism, applications must spell out how the two principal investigators and their institutions will work together in practice, including plans for communication, coordination of progress, sharing results, and transferring data. If the project involves multiple institutions, the application must also include an intellectual property plan intended to prevent institutional barriers from undermining cooperation, and to proactively address potential intellectual and material property issues that could interfere with completing the project effectively.

Administratively, the award requires two PIs: an Initiating PI, who takes primary responsibility for the submission and many administrative aspects, and a Partnering PI. Both are expected to contribute meaningfully to core components such as the Project Narrative and Statement of Work, and if funding is recommended, each PI will receive an individual award made within their respective organization. The application must clearly justify why the research question is best tackled through this linked partnership model rather than through separate, independent projects.

In terms of the basic opportunity details, this is a discretionary DoD program administered through the Department of Defense, Department of the Army (USAMRAA), with funding instruments that may include cooperative agreements and grants. The CFDA number listed is 12.420, eligibility is described as unrestricted (open to entity types, subject to any additional eligibility language in the full announcement), and the expected number of awards is four. The original FY21 posting was created on May 18, 2021, with an original closing date of October 1, 2021, under Funding Opportunity Number W81XWH-21-PCARP-TRPA.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Pancreatic Cancer, Translational Research Partnership Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on May 18, 2021.
• Applicants must submit their applications by Oct 01, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 4 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 PCARP TRPA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: